Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jan 18:10:353-4.
doi: 10.2147/DDDT.S100639. eCollection 2016.

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

Alejandro Gonzalez-Serna  1 , Miguel Genebat  2 , Ezequiel Ruiz-Mateos  2 , Manuel Leal  2
Affiliations
Comment

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

Alejandro Gonzalez-Serna et al. Drug Des Devel Ther. .
No abstract available

PubMed Disclaimer

Comment in

  • Author's reply.
    Woollard SM, Kanmogne GD. Woollard SM, et al. Drug Des Devel Ther. 2016;10:355-6. Drug Des Devel Ther. 2016. PMID: 27104225 No abstract available.

Comment on

Similar articles

  • Author's reply.
    Woollard SM, Kanmogne GD. Woollard SM, et al. Drug Des Devel Ther. 2016;10:355-6. Drug Des Devel Ther. 2016. PMID: 27104225 No abstract available.
  • Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM, Kanmogne GD. Woollard SM, et al. Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26491256 Free PMC article. Review.
  • Off-label use of maraviroc in clinical practice.
    Blanco JR, Ochoa-Callejero L. Blanco JR, et al. Expert Rev Anti Infect Ther. 2016;14(1):5-8. doi: 10.1586/14787210.2016.1100535. Epub 2015 Oct 28. Expert Rev Anti Infect Ther. 2016. PMID: 26509356 Review.
  • Clinical utility of maraviroc.
    Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.
  • Novel HIV treatment approved.
    Groeschen HM. Groeschen HM. Am J Health Syst Pharm. 2007 Sep 15;64(18):1886. doi: 10.2146/news070079. Am J Health Syst Pharm. 2007. PMID: 17823091 No abstract available.
See all similar articles

Cited by

References

    1. Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015;9:5447–5468. - PMC - PubMed
    1. Genebat M, Ruiz-Mateos E, Leon JA, et al. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother. 2009;64:845–849. - PubMed
    1. Gonzalez-Serna A, McGovern RA, Harrigan PR, et al. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods. Antimicrob Agents Chemother. 2012;56:1202–1207. - PMC - PubMed
    1. Hernández-Novoa B, Madrid-Elena N, Dronda F, et al. Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients. J Antimicrob Chemother. 2014;69:1916–1919. - PubMed
    1. Gonzalez-Serna A, Leal M, Genebat M, et al. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J Clin Microbiol. 2010;48:4453–4458. - PMC - PubMed

MeSH terms